Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.
Eli Lilly is dramatically slashing list prices for some of its most commonly prescribed insulins, as federal pressure grows to reduce the cost of the injections.
The company's announcement comes after President Joe Biden called in his State of the Union address for a $35 cap on monthly out-of-pocket costs for all diabetes patients. Lilly said it's introducing that cap for people with private insurance as well.
Some questioned what took Lilly so long and whether the other major manufacturers will follow suit. Meg has the rest of the story for us below.
Pfizer's and GSK's RSV vaccines for older adults took a step closer to approval this week, after securing endorsements from the FDA advisory committee.
Though a majority of the advisors backed the shots, there was substantial discussion and concern over rare nervous system disorders that several vaccine recipients developed during the trials, including Guillain-Barre syndrome.
There's an FDA decision date in May for both vaccines. It's unclear whether the safety concerns could delay the process or result in a warning label. The companies have said they will conduct post-marketing safety studies.
Feel free to send any tips, suggestions, story ideas and data to me at spencer.kimball@nbcuni.com.
Tidak ada komentar:
Posting Komentar